secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atea Pharmaceuticals, Inc. (AVIR)
CIK:        0001593899
Form:       8-K
Filed at:   2022-11-07T23:59:59+00:00
Accession:  0001193125-22-279097
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atea Pharma reports Q3 net loss $8.1M; cash $665M; SUNRISE-3 enrollment imminent
--------------------------------------------------------------------------------

- Net loss of $8.1M ($0.10 per share) vs net loss of $28.2M in Q3 2021.
- Cash and marketable securities $665.0M at Sept 30, 2022, down from $764.4M at Dec 31, 2021.
- R&D expenses fell to $4.9M from $43.0M, aided by a $14.5M credit from Roche cost share close-out.
- SUNRISE-3 Phase 3 trial for bemnifosbuvir in high-risk COVID-19 patients expected to start enrollment before year-end 2022.
- AT-752 human challenge study and DEFEND-2 first cohort completion expected around year-end; HCV trial submission also anticipated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593899/000119312522279097/0001193125-22-279097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593899/000119312522279097/d411939d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-279097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer